LADENBURG THALMANN FINANCIAL SERVICES INC. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2019$8,749,000
+87.7%
70,605
+0.5%
0.06%
+71.9%
Q3 2019$4,660,000
+2673.8%
70,222
+3245.5%
0.03%
+3100.0%
Q2 2019$168,000
-49.2%
2,099
-29.0%
0.00%
-66.7%
Q1 2019$331,000
+40.3%
2,958
+25.6%
0.00%
+50.0%
Q4 2018$236,000
-75.4%
2,355
-69.0%
0.00%
-75.0%
Q3 2018$961,000
-4.9%
7,599
-53.7%
0.01%
-11.1%
Q2 2018$1,010,0000.0%16,4220.0%0.01%0.0%
Q1 2018$1,010,000
+169.3%
16,422
+156.0%
0.01%
+125.0%
Q4 2017$375,000
-14.8%
6,415
-15.4%
0.00%
-20.0%
Q3 2017$440,000
+88.0%
7,582
+292.0%
0.01%
+66.7%
Q2 2017$234,000
+35.3%
1,934
+26.1%
0.00%
+50.0%
Q1 2017$173,000
-2.8%
1,534
-5.9%
0.00%0.0%
Q4 2016$178,000
-7.8%
1,630
+39.6%
0.00%
-33.3%
Q3 2016$193,000
+17.0%
1,168
+1.0%
0.00%0.0%
Q2 2016$165,000
+60.2%
1,156
+43.8%
0.00%
+50.0%
Q1 2016$103,000
-14.2%
804
+0.1%
0.00%0.0%
Q4 2015$120,000
-7.7%
803
+2.4%
0.00%
-33.3%
Q3 2015$130,000
-21.2%
784
+15.0%
0.00%0.0%
Q2 2015$165,000
-21.1%
682
-8.1%
0.00%
-25.0%
Q1 2015$209,000
+97.2%
742
+8.8%
0.00%
+100.0%
Q4 2014$106,000
-44.5%
682
-15.5%
0.00%
-60.0%
Q3 2014$191,000
+51.6%
807
+52.0%
0.01%
+66.7%
Q2 2014$126,000
+281.8%
531
+431.0%
0.00%
+200.0%
Q1 2014$33,0001000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2016
NameSharesValueWeighting ↓
Carmignac Gestion 2,028,192$229,389,0001.76%
Orbimed Advisors 1,037,000$117,285,0001.33%
BB BIOTECH AG 255,719$28,922,0000.95%
ALTRINSIC GLOBAL ADVISORS LLC 193,369$21,870,0000.74%
FALCON POINT CAPITAL, LLC 44,573$5,041,0000.67%
Rhenman & Partners Asset Management AB 30,000$3,393,0000.54%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 11,155$1,262,0000.48%
NATIONAL PLANNING CORP 52,400$5,888,0000.44%
HIGHFIELDS CAPITAL MANAGEMENT LP 364,232$41,195,0000.38%
SPHERA FUNDS MANAGEMENT LTD. 15,000$1,697,0000.33%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders